...
search icon
anro-img

Alto Neuroscience, Inc. Share Price

ANRO
NYQ
$18.12
-$1.14
(-5.92%)
1D
Industry: Pharmaceuticals Sector: Health Care

Alto Neuroscience, Inc. Analyst Forecast

Alto Neuroscience, Inc. Share Price Chart

Alto Neuroscience, Inc. Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$598.34M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
203.63K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.85
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.6 L
$20.91 H
$18.12

About Alto Neuroscience, Inc., Common Stock

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California. more

Industry: PharmaceuticalsSector: Health Care

Alto Neuroscience, Inc. Stock Returns

Time FrameANROSectorS&P500
1-Week Return15.26%0.72%-1.31%
1-Month Return10.56%1.27%0.78%
3-Month Return30.58%3.13%3.46%
6-Month Return464.81%15.81%6.19%
1-Year Return513.38%8.89%11.68%
3-Year Return20.38%20.79%71.21%

Alto Neuroscience, Inc. Financials

Sep '21Sep '22Sep '23Sep '24
Total Revenue210.00K---[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Cost of Revenue145.00K342.00K373.00K502.00K[{"date":"2021-09-30","value":28.88,"profit":true},{"date":"2022-09-30","value":68.13,"profit":true},{"date":"2023-09-30","value":74.3,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Gross Profit65.00K(342.00K)(373.00K)(502.00K)[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-526.15,"profit":false},{"date":"2023-09-30","value":-573.85,"profit":false},{"date":"2024-09-30","value":-772.31,"profit":false}]
Gross Margin30.95%---[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Operating Expenses12.12M28.85M37.81M68.11M[{"date":"2021-09-30","value":17.8,"profit":true},{"date":"2022-09-30","value":42.36,"profit":true},{"date":"2023-09-30","value":55.51,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Operating Income(12.06M)(29.19M)(37.81M)(68.61M)[{"date":"2021-09-30","value":-1205600000,"profit":false},{"date":"2022-09-30","value":-2919200000,"profit":false},{"date":"2023-09-30","value":-3780900000,"profit":false},{"date":"2024-09-30","value":-6861000000,"profit":false}]
Total Non-Operating Income/Expense2.87M1.60M2.48M14.65M[{"date":"2021-09-30","value":19.59,"profit":true},{"date":"2022-09-30","value":10.89,"profit":true},{"date":"2023-09-30","value":16.94,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Pre-Tax Income(9.19M)(27.71M)(36.30M)(61.43M)[{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false},{"date":"2024-09-30","value":-6143100000,"profit":false}]
Income Taxes---(61.43M)[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":-6143100000,"profit":false}]
Income After Taxes----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Income From Continuous Operations(9.19M)(27.71M)(36.30M)(61.43M)[{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false},{"date":"2024-09-30","value":-6143100000,"profit":false}]
Income From Discontinued Operations----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Net Income(9.19M)(27.71M)(36.30M)(61.43M)[{"date":"2021-09-30","value":-918700000,"profit":false},{"date":"2022-09-30","value":-2771000000,"profit":false},{"date":"2023-09-30","value":-3630500000,"profit":false},{"date":"2024-09-30","value":-6143100000,"profit":false}]
EPS (Diluted)---(9.75)[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":-975,"profit":false}]

Alto Neuroscience, Inc. Ratios

Alto Neuroscience, Inc. Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

ANRO
Cash Ratio 15.24
Current Ratio 15.42

Alto Neuroscience, Inc. Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANRO
ROA (LTM) -24.48%
ROE (LTM) -45.01%

Alto Neuroscience, Inc. Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANRO
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Alto Neuroscience, Inc. Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANRO
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 4.70
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Alto Neuroscience, Inc. share price today?

Alto Neuroscience, Inc. (ANRO) share price today is $18.12

Can Indians buy Alto Neuroscience, Inc. shares?

Yes, Indians can buy shares of Alto Neuroscience, Inc. (ANRO) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alto Neuroscience, Inc. be purchased?

Yes, you can purchase fractional shares of Alto Neuroscience, Inc. (ANRO) via the Vested app. You can start investing in Alto Neuroscience, Inc. (ANRO) with a minimum investment of $1.

How to invest in Alto Neuroscience, Inc. shares from India?

You can invest in shares of Alto Neuroscience, Inc. (ANRO) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANRO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alto Neuroscience, Inc. shares
What is Alto Neuroscience, Inc. 52-week high and low stock price?

The 52-week high price of Alto Neuroscience, Inc. (ANRO) is $20.91. The 52-week low price of Alto Neuroscience, Inc. (ANRO) is $1.6.

What is Alto Neuroscience, Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Alto Neuroscience, Inc. (ANRO) is

What is Alto Neuroscience, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alto Neuroscience, Inc. (ANRO) is 4.70

What is Alto Neuroscience, Inc. dividend yield?

The dividend yield of Alto Neuroscience, Inc. (ANRO) is 0.00%

What is the Market Cap of Alto Neuroscience, Inc.?

The market capitalization of Alto Neuroscience, Inc. (ANRO) is $598.34M

What is Alto Neuroscience, Inc.'s stock symbol?

The stock symbol (or ticker) of Alto Neuroscience, Inc. is ANRO

How Can Investors Use Alto Neuroscience, Inc. Share Price Data for Long-Term Investment Decisions?

Consider the share price of Alto Neuroscience, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Alto Neuroscience, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Alto Neuroscience, Inc. shares for Indian investors?

When investing in Alto Neuroscience, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Alto Neuroscience, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Alto Neuroscience, Inc. share price with other stocks in the same sector?

Rather than merely checking the share price of Alto Neuroscience, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Alto Neuroscience, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top